Assessment	B:C0220825
of	O
cerebral	O
blood	O
perfusion	O
reserve	O
with	O
acetazolamide	O
using	O
3D	O
spiral	I:C3891302
ASL	I:C3891302
MRI	I:C3891302
:	O
Preliminary	O
experience	O
in	O
pediatric	O
patients	O
.	O

Assessment	O
of	O
cerebral	B:C0006104
blood	O
perfusion	O
reserve	O
with	O
acetazolamide	O
using	O
3D	O
spiral	I:C3891302
ASL	I:C3891302
MRI	I:C3891302
:	O
Preliminary	O
experience	O
in	O
pediatric	O
patients	O
.	O

Assessment	O
of	O
cerebral	O
blood	O
perfusion	O
reserve	O
with	O
acetazolamide	B:C0000981
using	O
3D	O
spiral	I:C3891302
ASL	I:C3891302
MRI	I:C3891302
:	O
Preliminary	O
experience	O
in	O
pediatric	O
patients	O
.	O

Assessment	O
of	O
cerebral	O
blood	O
perfusion	O
reserve	O
with	O
acetazolamide	O
using	O
3D	B:C3891302
spiral	I:C3891302
ASL	I:C3891302
MRI	I:C3891302
:	O
Preliminary	O
experience	O
in	O
pediatric	O
patients	O
.	O

To	O
demonstrate	O
the	O
clinical	B:C0015730
feasibility	I:C0015730
of	O
a	O
new	O
non-Cartesian	O
cylindrically	I:C3891302
-	I:C3891302
distributed	I:C3891302
spiral	I:C3891302
3D	I:C3891302
pseudo	I:C3891302
-	I:C3891302
continuous	I:C3891302
arterial	I:C3891302
spin	I:C3891302
labeling	I:C3891302
(	I:C3891302
pCASL	I:C3891302
)	I:C3891302
magnetic	I:C3891302
resonance	I:C3891302
imaging	I:C3891302
(	I:C3891302
MRI	I:C3891302
)	I:C3891302
pulse	O
sequence	I:C3828438
in	O
pediatric	O
patients	O
in	O
quantifying	O
cerebral	O
blood	I:C0428714
flow	I:C0428714
(	O
cerebral	O
blood	I:C0428714
flow	I:C0428714
)	O
response	O
to	O
an	O
acetazolamide	O
(	I:C0042402
ACZ	I:C0042402
)	I:C0042402
vasodilator	I:C0042402
challenge	O
.	O

To	O
demonstrate	O
the	O
clinical	O
feasibility	I:C0015730
of	O
a	O
new	O
non-Cartesian	B:C3891302
cylindrically	I:C3891302
-	I:C3891302
distributed	I:C3891302
spiral	I:C3891302
3D	I:C3891302
pseudo	I:C3891302
-	I:C3891302
continuous	I:C3891302
arterial	I:C3891302
spin	I:C3891302
labeling	I:C3891302
(	I:C3891302
pCASL	I:C3891302
)	I:C3891302
magnetic	I:C3891302
resonance	I:C3891302
imaging	I:C3891302
(	I:C3891302
MRI	I:C3891302
)	I:C3891302
pulse	O
sequence	I:C3828438
in	O
pediatric	O
patients	O
in	O
quantifying	O
cerebral	O
blood	I:C0428714
flow	I:C0428714
(	O
cerebral	O
blood	I:C0428714
flow	I:C0428714
)	O
response	O
to	O
an	O
acetazolamide	O
(	I:C0042402
ACZ	I:C0042402
)	I:C0042402
vasodilator	I:C0042402
challenge	O
.	O

To	O
demonstrate	O
the	O
clinical	O
feasibility	I:C0015730
of	O
a	O
new	O
non-Cartesian	O
cylindrically	I:C3891302
-	I:C3891302
distributed	I:C3891302
spiral	I:C3891302
3D	I:C3891302
pseudo	I:C3891302
-	I:C3891302
continuous	I:C3891302
arterial	I:C3891302
spin	I:C3891302
labeling	I:C3891302
(	I:C3891302
pCASL	I:C3891302
)	I:C3891302
magnetic	I:C3891302
resonance	I:C3891302
imaging	I:C3891302
(	I:C3891302
MRI	I:C3891302
)	I:C3891302
pulse	B:C3828438
sequence	I:C3828438
in	O
pediatric	O
patients	O
in	O
quantifying	O
cerebral	O
blood	I:C0428714
flow	I:C0428714
(	O
cerebral	O
blood	I:C0428714
flow	I:C0428714
)	O
response	O
to	O
an	O
acetazolamide	O
(	I:C0042402
ACZ	I:C0042402
)	I:C0042402
vasodilator	I:C0042402
challenge	O
.	O

To	O
demonstrate	O
the	O
clinical	O
feasibility	I:C0015730
of	O
a	O
new	O
non-Cartesian	O
cylindrically	I:C3891302
-	I:C3891302
distributed	I:C3891302
spiral	I:C3891302
3D	I:C3891302
pseudo	I:C3891302
-	I:C3891302
continuous	I:C3891302
arterial	I:C3891302
spin	I:C3891302
labeling	I:C3891302
(	I:C3891302
pCASL	I:C3891302
)	I:C3891302
magnetic	I:C3891302
resonance	I:C3891302
imaging	I:C3891302
(	I:C3891302
MRI	I:C3891302
)	I:C3891302
pulse	O
sequence	I:C3828438
in	O
pediatric	O
patients	O
in	O
quantifying	O
cerebral	B:C0428714
blood	I:C0428714
flow	I:C0428714
(	O
cerebral	O
blood	I:C0428714
flow	I:C0428714
)	O
response	O
to	O
an	O
acetazolamide	O
(	I:C0042402
ACZ	I:C0042402
)	I:C0042402
vasodilator	I:C0042402
challenge	O
.	O

To	O
demonstrate	O
the	O
clinical	O
feasibility	I:C0015730
of	O
a	O
new	O
non-Cartesian	O
cylindrically	I:C3891302
-	I:C3891302
distributed	I:C3891302
spiral	I:C3891302
3D	I:C3891302
pseudo	I:C3891302
-	I:C3891302
continuous	I:C3891302
arterial	I:C3891302
spin	I:C3891302
labeling	I:C3891302
(	I:C3891302
pCASL	I:C3891302
)	I:C3891302
magnetic	I:C3891302
resonance	I:C3891302
imaging	I:C3891302
(	I:C3891302
MRI	I:C3891302
)	I:C3891302
pulse	O
sequence	I:C3828438
in	O
pediatric	O
patients	O
in	O
quantifying	O
cerebral	O
blood	I:C0428714
flow	I:C0428714
(	O
cerebral	B:C0428714
blood	I:C0428714
flow	I:C0428714
)	O
response	O
to	O
an	O
acetazolamide	O
(	I:C0042402
ACZ	I:C0042402
)	I:C0042402
vasodilator	I:C0042402
challenge	O
.	O

To	O
demonstrate	O
the	O
clinical	O
feasibility	I:C0015730
of	O
a	O
new	O
non-Cartesian	O
cylindrically	I:C3891302
-	I:C3891302
distributed	I:C3891302
spiral	I:C3891302
3D	I:C3891302
pseudo	I:C3891302
-	I:C3891302
continuous	I:C3891302
arterial	I:C3891302
spin	I:C3891302
labeling	I:C3891302
(	I:C3891302
pCASL	I:C3891302
)	I:C3891302
magnetic	I:C3891302
resonance	I:C3891302
imaging	I:C3891302
(	I:C3891302
MRI	I:C3891302
)	I:C3891302
pulse	O
sequence	I:C3828438
in	O
pediatric	O
patients	O
in	O
quantifying	O
cerebral	O
blood	I:C0428714
flow	I:C0428714
(	O
cerebral	O
blood	I:C0428714
flow	I:C0428714
)	O
response	O
to	O
an	O
acetazolamide	B:C0042402
(	I:C0042402
ACZ	I:C0042402
)	I:C0042402
vasodilator	I:C0042402
challenge	O
.	O

MRI	B:C0024485
exams	I:C0024485
were	O
performed	O
on	O
two	O
3	O
Tesla	O
Philips	O
Ingenia	O
systems	O
using	O
32	O
channel	O
head	O
coil	O
arrays	O
.	O

After	O
local	O
institutional	B:C2346499
review	I:C2346499
board	I:C2346499
approval	I:C2346499
,	O
the	O
3D	O
spiral	I:C3891302
-	I:C3891302
based	I:C3891302
pCASL	I:C3891302
technique	I:C3891302
was	O
added	O
to	O
a	O
standard	O
brain	O
MRI	I:C0412675
exam	I:C0412675
and	O
evaluated	O
in	O
13	O
pediatric	O
patients	O
(	O
average	O
age	O
:	O
11.7±6.4years	O
,	O
range	O
:	O
1.4-22.2years	O
)	O
.	O

After	O
local	O
institutional	O
review	I:C2346499
board	I:C2346499
approval	I:C2346499
,	O
the	O
3D	B:C3891302
spiral	I:C3891302
-	I:C3891302
based	I:C3891302
pCASL	I:C3891302
technique	I:C3891302
was	O
added	O
to	O
a	O
standard	O
brain	O
MRI	I:C0412675
exam	I:C0412675
and	O
evaluated	O
in	O
13	O
pediatric	O
patients	O
(	O
average	O
age	O
:	O
11.7±6.4years	O
,	O
range	O
:	O
1.4-22.2years	O
)	O
.	O

After	O
local	O
institutional	O
review	I:C2346499
board	I:C2346499
approval	I:C2346499
,	O
the	O
3D	O
spiral	I:C3891302
-	I:C3891302
based	I:C3891302
pCASL	I:C3891302
technique	I:C3891302
was	O
added	O
to	O
a	O
standard	O
brain	B:C0412675
MRI	I:C0412675
exam	I:C0412675
and	O
evaluated	O
in	O
13	O
pediatric	O
patients	O
(	O
average	O
age	O
:	O
11.7±6.4years	O
,	O
range	O
:	O
1.4-22.2years	O
)	O
.	O

All	O
patients	O
were	O
administered	B:C3469597
acetazolamide	O
for	O
clinically	O
indicated	I:C2985739
reasons	O
.	O

All	O
patients	O
were	O
administered	O
acetazolamide	B:C0000981
for	O
clinically	O
indicated	I:C2985739
reasons	O
.	O

All	O
patients	O
were	O
administered	O
acetazolamide	O
for	O
clinically	B:C2985739
indicated	I:C2985739
reasons	O
.	O

Quantitative	O
whole	B:C0005776
-	I:C0005776
brain	I:C0005776
CBF	I:C0005776
measurements	I:C0005776
were	O
computed	O
pre	O
-	O
and	O
post	O
-	O
acetazolamide	O
to	O
assess	O
cerebrovascular	O
reserve	I:C0007818
.	O

Quantitative	O
whole	O
-	I:C0005776
brain	I:C0005776
CBF	I:C0005776
measurements	I:C0005776
were	O
computed	O
pre	O
-	O
and	O
post	O
-	O
acetazolamide	B:C0000981
to	O
assess	O
cerebrovascular	O
reserve	I:C0007818
.	O

Quantitative	O
whole	O
-	I:C0005776
brain	I:C0005776
CBF	I:C0005776
measurements	I:C0005776
were	O
computed	O
pre	O
-	O
and	O
post	O
-	O
acetazolamide	O
to	O
assess	O
cerebrovascular	B:C0007818
reserve	I:C0007818
.	O

3D	B:C3891302
spiral	I:C3891302
pCASL	I:C3891302
data	O
were	O
successfully	O
reconstructed	O
in	O
all	O
13	O
cases	O
.	O

3D	O
spiral	I:C3891302
pCASL	I:C3891302
data	O
were	O
successfully	O
reconstructed	O
in	O
all	O
13	O
cases	B:C0150093
.	O

In	O
11	O
patients	O
,	O
cerebral	B:C0428714
blood	I:C0428714
flow	I:C0428714
increased	O
2.8	O
%	O
to	O
93.2	O
%	O
after	O
administration	O
of	I:C3469597
acetazolamide	O
.	O

In	O
11	O
patients	O
,	O
cerebral	O
blood	I:C0428714
flow	I:C0428714
increased	O
2.8	O
%	O
to	O
93.2	O
%	O
after	O
administration	B:C3469597
of	I:C3469597
acetazolamide	O
.	O

In	O
11	O
patients	O
,	O
cerebral	O
blood	I:C0428714
flow	I:C0428714
increased	O
2.8	O
%	O
to	O
93.2	O
%	O
after	O
administration	O
of	I:C3469597
acetazolamide	B:C0000981
.	O

In	O
the	O
two	O
remaining	O
patients	O
,	O
cerebral	B:C0428714
blood	I:C0428714
flow	I:C0428714
decreased	O
by	O
2.4	O
to	O
6.0	O
%	O
after	O
acetazolamide	O
.	O

In	O
the	O
two	O
remaining	O
patients	O
,	O
cerebral	O
blood	I:C0428714
flow	I:C0428714
decreased	O
by	O
2.4	O
to	O
6.0	O
%	O
after	O
acetazolamide	B:C0000981
.	O

The	O
group	O
average	O
change	O
in	O
cerebral	B:C0428714
blood	I:C0428714
flow	I:C0428714
due	O
to	O
acetazolamide	O
was	O
approximately	O
25.0	O
%	O
and	O
individual	O
changes	O
were	O
statistically	O
significant	O
(	O
p<0.01	O
)	O
in	O
all	O
patients	O
using	O
a	O
paired	O
t-	O
test	I:C0871472
analysis	I:C0871472
.	O

The	O
group	O
average	O
change	O
in	O
cerebral	O
blood	I:C0428714
flow	I:C0428714
due	O
to	O
acetazolamide	B:C0000981
was	O
approximately	O
25.0	O
%	O
and	O
individual	O
changes	O
were	O
statistically	O
significant	O
(	O
p<0.01	O
)	O
in	O
all	O
patients	O
using	O
a	O
paired	O
t-	O
test	I:C0871472
analysis	I:C0871472
.	O

The	O
group	O
average	O
change	O
in	O
cerebral	O
blood	I:C0428714
flow	I:C0428714
due	O
to	O
acetazolamide	O
was	O
approximately	O
25.0	O
%	O
and	O
individual	O
changes	O
were	O
statistically	O
significant	O
(	O
p<0.01	O
)	O
in	O
all	O
patients	O
using	O
a	O
paired	O
t-	B:C0871472
test	I:C0871472
analysis	I:C0871472
.	O

cerebral	B:C0428714
blood	I:C0428714
flow	I:C0428714
perfusion	O
data	O
were	O
diagnostically	O
useful	O
in	O
supporting	O
conventional	O
MR	O
angiography	I:C1636167
and	O
clinical	O
findings	I:C0455712
.	O

cerebral	O
blood	I:C0428714
flow	I:C0428714
perfusion	O
data	O
were	O
diagnostically	O
useful	O
in	O
supporting	O
conventional	O
MR	B:C1636167
angiography	I:C1636167
and	O
clinical	O
findings	I:C0455712
.	O

cerebral	O
blood	I:C0428714
flow	I:C0428714
perfusion	O
data	O
were	O
diagnostically	O
useful	O
in	O
supporting	O
conventional	O
MR	O
angiography	I:C1636167
and	O
clinical	B:C0455712
findings	I:C0455712
.	O

3D	B:C3891302
cylindrically	I:C3891302
-	I:C3891302
distributed	I:C3891302
spiral	I:C3891302
pCASL	I:C3891302
MRI	I:C3891302
provides	O
a	O
robust	O
approach	O
to	O
assess	O
cerebral	O
blood	I:C0428714
flow	I:C0428714
and	O
reserve	O
in	O
pediatric	O
patients	O
.	O

3D	O
cylindrically	I:C3891302
-	I:C3891302
distributed	I:C3891302
spiral	I:C3891302
pCASL	I:C3891302
MRI	I:C3891302
provides	O
a	O
robust	O
approach	O
to	O
assess	O
cerebral	B:C0428714
blood	I:C0428714
flow	I:C0428714
and	O
reserve	O
in	O
pediatric	O
patients	O
.	O

